Nasdaq · CIK 0001557746
ACRS Aclaris Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 9, 2025. Close $3.83 on Oct 9, 2026, +112% from the 52-week low and -41% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
ACRSOct 9, 2026 · close 3.83
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Aclaris Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Anand Mehra director buy | $1.5M 666,666 shares | +1537% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 6, 2025 | William D. Humphries director | MOption exercise Common Stock | +4,793 | - | - | 33,525 | Jun 9, 2025 |
| Jun 6, 2025 | Christopher P. Molineaux director | MOption exercise Common Stock | +4,793 | - | - | 57,956 | Jun 9, 2025 |
| Jun 6, 2025 | Vincent Milano director | MOption exercise Common Stock | +4,793 | - | - | 17,316 | Jun 9, 2025 |
| Jun 6, 2025 | Anand Mehra director | MOption exercise Common Stock | +4,793 | - | - | 714,823 | Jun 9, 2025 |
| Jun 6, 2025 | Maxine Gowen director | MOption exercise Common Stock | +4,793 | - | - | 21,754 | Jun 9, 2025 |
| Jun 6, 2025 | Andrew N Schiff director | MOption exercise Common Stock | +4,793 | - | - | 13,960 | Jun 9, 2025 |
| Jun 5, 2025 | William D. Humphries director | AGrant or award Stock Option (Right to Buy)derivative | +42,350 | $0.00 | $0 | 42,350 | Jun 9, 2025 |
| Jun 5, 2025 | Vincent Milano director | AGrant or award Stock Option (Right to Buy)derivative | +42,350 | $0.00 | $0 | 42,350 | Jun 9, 2025 |
| Jun 5, 2025 | Christopher P. Molineaux director | AGrant or award Stock Option (Right to Buy)derivative | +42,350 | $0.00 | $0 | 42,350 | Jun 9, 2025 |
| Jun 5, 2025 | Anand Mehra director | AGrant or award Stock Option (Right to Buy)derivative | +42,350 | $0.00 | $0 | 42,350 | Jun 9, 2025 |
| Jun 5, 2025 | Maxine Gowen director | AGrant or award Stock Option (Right to Buy)derivative | +42,350 | $0.00 | $0 | 42,350 | Jun 9, 2025 |
| Jun 5, 2025 | Vincent Milano director | AGrant or award Restricted Stock Unitsderivative | +11,580 | $0.00 | $0 | 11,580 | Jun 9, 2025 |
| Jun 5, 2025 | William D. Humphries director | AGrant or award Restricted Stock Unitsderivative | +11,580 | $0.00 | $0 | 11,580 | Jun 9, 2025 |
| Jun 5, 2025 | Andrew N Schiff director | AGrant or award Stock Option (Right to Buy)derivative | +42,350 | $0.00 | $0 | 42,350 | Jun 9, 2025 |
| Jun 5, 2025 | Anand Mehra director | AGrant or award Restricted Stock Unitsderivative | +11,580 | $0.00 | $0 | 11,580 | Jun 9, 2025 |
| Jun 5, 2025 | Maxine Gowen director | AGrant or award Restricted Stock Unitsderivative | +11,580 | $0.00 | $0 | 11,580 | Jun 9, 2025 |
| Jun 5, 2025 | Christopher P. Molineaux director | AGrant or award Restricted Stock Unitsderivative | +11,580 | $0.00 | $0 | 11,580 | Jun 9, 2025 |
| Jun 6, 2025 | Vincent Milano director | MOption exercise Restricted Stock Unitsderivative | -4,793 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Maxine Gowen director | MOption exercise Restricted Stock Unitsderivative | -4,793 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Anand Mehra director | MOption exercise Restricted Stock Unitsderivative | -4,793 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 5, 2025 | Andrew N Schiff director | AGrant or award Restricted Stock Unitsderivative | +11,580 | $0.00 | $0 | 11,580 | Jun 9, 2025 |
| Jun 6, 2025 | Christopher P. Molineaux director | MOption exercise Restricted Stock Unitsderivative | -4,793 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | William D. Humphries director | MOption exercise Restricted Stock Unitsderivative | -4,793 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Jun 6, 2025 | Andrew N Schiff director | MOption exercise Restricted Stock Unitsderivative | -4,793 | $0.00 | $0 | 0 | Jun 9, 2025 |
| May 1, 2025 | Jesse Wayne Hall Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +145,500 | $0.00 | $0 | 145,500 | May 5, 2025 |
| May 1, 2025 | Neal Walker CEO | MOption exercise Common Stock | +9,467 | - | - | 1,482,799 | May 5, 2025 |
| May 1, 2025 | Neal Walker CEO | FTax withholding Common Stock | -2,975 | $1.38 | $4,106 | 1,479,824 | May 5, 2025 |
| May 1, 2025 | Jesse Wayne Hall Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +510,000 | $0.00 | $0 | 510,000 | May 5, 2025 |
| May 1, 2025 | Neal Walker CEO | MOption exercise Restricted Stock Unitsderivative | -9,467 | $0.00 | $0 | 0 | May 5, 2025 |
| Apr 1, 2025 | Neal Walker CEO | MOption exercise Common Stock | +9,467 | - | - | 1,476,374 | Apr 3, 2025 |
| Apr 1, 2025 | Neal Walker CEO | FTax withholding Common Stock | -3,042 | $1.48 | $4,502 | 1,473,332 | Apr 3, 2025 |
| Apr 1, 2025 | Neal Walker CEO | MOption exercise Restricted Stock Unitsderivative | -9,467 | $0.00 | $0 | 9,467 | Apr 3, 2025 |
| Mar 1, 2025 | Joseph Monahan Chief Scientific Officer | MOption exercise Common Stock | +50,000 | - | - | 281,995 | Mar 4, 2025 |
| Mar 1, 2025 | Neal Walker CEO | MOption exercise Common Stock | +9,466 | - | - | 1,470,184 | Mar 4, 2025 |
| Mar 1, 2025 | Kevin Balthaser Chief Financial Officer | MOption exercise Common Stock | +1,100 | - | - | 90,960 | Mar 4, 2025 |
| Mar 1, 2025 | Kevin Balthaser Chief Financial Officer | MOption exercise Common Stock | +2,375 | - | - | 93,335 | Mar 4, 2025 |
| Mar 1, 2025 | Joseph Monahan Chief Scientific Officer | MOption exercise Common Stock | +10,925 | - | - | 292,920 | Mar 4, 2025 |
| Mar 1, 2025 | Neal Walker CEO | FTax withholding Common Stock | -3,277 | $1.99 | $6,521 | 1,466,907 | Mar 4, 2025 |
| Mar 1, 2025 | Kevin Balthaser Chief Financial Officer | FTax withholding Common Stock | -727 | $1.99 | $1,447 | 92,608 | Mar 4, 2025 |
| Mar 1, 2025 | Joseph Monahan Chief Scientific Officer | FTax withholding Common Stock | -27,258 | $1.99 | $54k | 265,662 | Mar 4, 2025 |
| Mar 1, 2025 | Neal Walker CEO | MOption exercise Restricted Stock Unitsderivative | -9,466 | $0.00 | $0 | 18,934 | Mar 4, 2025 |
| Mar 1, 2025 | Kevin Balthaser Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -1,100 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 1, 2025 | Kevin Balthaser Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -2,375 | $0.00 | $0 | 2,375 | Mar 4, 2025 |
| Mar 1, 2025 | Joseph Monahan Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -50,000 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 1, 2025 | Joseph Monahan Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -10,925 | $0.00 | $0 | 10,925 | Mar 4, 2025 |
| Feb 1, 2025 | Neal Walker INTERIM CEO | MOption exercise Common Stock | +9,467 | - | - | 1,464,277 | Feb 4, 2025 |
| Feb 1, 2025 | Joseph Monahan Chief Scientific Officer | MOption exercise Common Stock | +7,500 | - | - | 228,562 | Feb 4, 2025 |
| Feb 3, 2025 | Hugh M. Davis President and COO | AGrant or award Restricted Stock Unitsderivative | +74,700 | $0.00 | $0 | 74,700 | Feb 4, 2025 |
| Feb 1, 2025 | James Loerop Chief Business Officer | MOption exercise Common Stock | +11,250 | - | - | 96,503 | Feb 4, 2025 |
| Feb 1, 2025 | Kevin Balthaser Chief Financial Officer | MOption exercise Common Stock | +14,750 | - | - | 95,676 | Feb 4, 2025 |
| Feb 1, 2025 | Kevin Balthaser Chief Financial Officer | FTax withholding Common Stock | -5,816 | $2.48 | $14k | 89,860 | Feb 4, 2025 |
| Feb 1, 2025 | Joseph Monahan Chief Scientific Officer | MOption exercise Common Stock | +14,750 | - | - | 243,312 | Feb 4, 2025 |
| Feb 1, 2025 | Neal Walker INTERIM CEO | FTax withholding Common Stock | -3,559 | $2.48 | $8,826 | 1,460,718 | Feb 4, 2025 |
| Feb 3, 2025 | Hugh M. Davis President and COO | AGrant or award Employee Stock Option (Right to Buy)derivative | +261,600 | $0.00 | $0 | 261,600 | Feb 4, 2025 |
| Feb 1, 2025 | James Loerop Chief Business Officer | MOption exercise Common Stock | +7,500 | - | - | 104,003 | Feb 4, 2025 |
| Feb 1, 2025 | Kevin Balthaser Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -14,750 | $0.00 | $0 | 44,250 | Feb 4, 2025 |
| Feb 1, 2025 | Joseph Monahan Chief Scientific Officer | FTax withholding Common Stock | -11,317 | $2.48 | $28k | 231,995 | Feb 4, 2025 |
| Feb 1, 2025 | Neal Walker INTERIM CEO | MOption exercise Restricted Stock Unitsderivative | -9,467 | $0.00 | $0 | 28,400 | Feb 4, 2025 |
| Feb 1, 2025 | James Loerop Chief Business Officer | MOption exercise Common Stock | +14,750 | - | - | 118,753 | Feb 4, 2025 |
| Feb 3, 2025 | Kevin Balthaser Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +88,100 | $0.00 | $0 | 88,100 | Feb 4, 2025 |
| Feb 3, 2025 | Neal Walker INTERIM CEO | AGrant or award Restricted Stock Unitsderivative | +253,900 | $0.00 | $0 | 253,900 | Feb 4, 2025 |
| Feb 1, 2025 | James Loerop Chief Business Officer | FTax withholding Common Stock | -15,447 | $2.48 | $38k | 103,306 | Feb 4, 2025 |
| Feb 1, 2025 | Joseph Monahan Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -7,500 | $0.00 | $0 | 15,000 | Feb 4, 2025 |
| Feb 3, 2025 | Kevin Balthaser Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +308,200 | $0.00 | $0 | 308,200 | Feb 4, 2025 |
| Feb 3, 2025 | Neal Walker INTERIM CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +888,800 | $0.00 | $0 | 888,800 | Feb 4, 2025 |
| Feb 1, 2025 | James Loerop Chief Business Officer | MOption exercise Restricted Stock Unitsderivative | -11,250 | $0.00 | $0 | 11,250 | Feb 4, 2025 |
| Feb 1, 2025 | Joseph Monahan Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -14,750 | $0.00 | $0 | 44,250 | Feb 4, 2025 |
| Feb 1, 2025 | James Loerop Chief Business Officer | MOption exercise Resticted Stock Unitsderivative | -7,500 | $0.00 | $0 | 15,000 | Feb 4, 2025 |
| Feb 3, 2025 | Joseph Monahan Chief Scientific Officer | AGrant or award Restricted Stock Unitsderivative | +83,900 | $0.00 | $0 | 83,900 | Feb 4, 2025 |
| Feb 1, 2025 | James Loerop Chief Business Officer | MOption exercise Restricted Stock Unitsderivative | -14,750 | $0.00 | $0 | 44,250 | Feb 4, 2025 |
| Feb 3, 2025 | Joseph Monahan Chief Scientific Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +293,500 | $0.00 | $0 | 293,500 | Feb 4, 2025 |
| Feb 3, 2025 | James Loerop Chief Business Officer | AGrant or award Restricted Stock Unitsderivative | +83,500 | $0.00 | $0 | 83,500 | Feb 4, 2025 |
| Feb 3, 2025 | James Loerop Chief Business Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +292,300 | $0.00 | $0 | 292,300 | Feb 4, 2025 |
| Dec 31, 2024 | Joseph Monahan Chief Scientific Officer | MOption exercise Common Stock | +73,750 | - | - | 245,533 | Jan 3, 2025 |
| Jan 1, 2025 | Neal Walker INTERIM CEO | MOption exercise Common Stock | +9,467 | - | - | 1,443,097 | Jan 3, 2025 |
| Dec 31, 2024 | James Loerop Chief Business Officer | MOption exercise Common Stock | +73,750 | - | - | 107,767 | Jan 3, 2025 |
| Dec 31, 2024 | Kevin Balthaser Chief Financial Officer | MOption exercise Common Stock | +73,750 | - | - | 98,447 | Jan 3, 2025 |
| Jan 1, 2025 | Neal Walker INTERIM CEO | FTax withholding Common Stock | -3,904 | $2.48 | $9,682 | 1,439,193 | Jan 3, 2025 |
| Dec 31, 2024 | Joseph Monahan Chief Scientific Officer | FTax withholding Common Stock | -32,937 | - | - | 212,596 | Jan 3, 2025 |
| Dec 31, 2024 | James Loerop Chief Business Officer | FTax withholding Common Stock | -32,089 | $2.48 | $80k | 75,678 | Jan 3, 2025 |
| Dec 31, 2024 | Kevin Balthaser Chief Financial Officer | FTax withholding Common Stock | -30,732 | $2.48 | $76k | 67,715 | Jan 3, 2025 |
| Jan 2, 2025 | Neal Walker INTERIM CEO | MOption exercise Common Stock | +29,149 | - | - | 1,468,342 | Jan 3, 2025 |
| Jan 2, 2025 | James Loerop Chief Business Officer | MOption exercise Common Stock | +18,150 | - | - | 93,828 | Jan 3, 2025 |
| Jan 2, 2025 | Joseph Monahan Chief Scientific Officer | MOption exercise Common Stock | +17,380 | - | - | 229,976 | Jan 3, 2025 |
| Jan 1, 2025 | Kevin Balthaser Chief Financial Officer | MOption exercise Common Stock | +7,500 | - | - | 75,215 | Jan 3, 2025 |
| Jan 2, 2025 | Neal Walker INTERIM CEO | FTax withholding Common Stock | -13,532 | $2.48 | $34k | 1,454,810 | Jan 3, 2025 |
| Jan 2, 2025 | James Loerop Chief Business Officer | FTax withholding Common Stock | -8,575 | $2.48 | $21k | 85,253 | Jan 3, 2025 |
| Jan 2, 2025 | Joseph Monahan Chief Scientific Officer | FTax withholding Common Stock | -8,914 | - | - | 221,062 | Jan 3, 2025 |
| Jan 1, 2025 | Kevin Balthaser Chief Financial Officer | FTax withholding Common Stock | -2,430 | $2.48 | $6,026 | 72,785 | Jan 3, 2025 |
| Jan 2, 2025 | Kevin Balthaser Chief Financial Officer | MOption exercise Common Stock | +13,200 | - | - | 85,985 | Jan 3, 2025 |
| Jan 1, 2025 | Neal Walker INTERIM CEO | MOption exercise Restricted Stock Unitsderivative | -9,467 | $0.00 | $0 | 37,867 | Jan 3, 2025 |
| Dec 31, 2024 | James Loerop Chief Business Officer | MOption exercise Restricted Stock Unitsderivative | -73,750 | $0.00 | $0 | 73,750 | Jan 3, 2025 |
| Jan 2, 2025 | Neal Walker INTERIM CEO | AGrant or award Restricted Stock Unitsderivative | +88,333 | $0.00 | $0 | 88,333 | Jan 3, 2025 |
| Jan 2, 2025 | James Loerop Chief Business Officer | AGrant or award Restricted Stock Unitsderivative | +55,000 | $0.00 | $0 | 55,000 | Jan 3, 2025 |
| Jan 2, 2025 | Kevin Balthaser Chief Financial Officer | FTax withholding Common Stock | -5,059 | $2.48 | $13k | 80,926 | Jan 3, 2025 |
| Dec 31, 2024 | Joseph Monahan Chief Scientific Officer | MOption exercise Restricted Stock Unitsderivative | -73,750 | $0.00 | $0 | 73,750 | Jan 3, 2025 |
| Jan 2, 2025 | Neal Walker INTERIM CEO | MOption exercise Restricted Stock Unitsderivative | -29,149 | $0.00 | $0 | 59,184 | Jan 3, 2025 |
| Jan 2, 2025 | James Loerop Chief Business Officer | MOption exercise Restricted Stock Unitsderivative | -18,150 | $0.00 | $0 | 36,850 | Jan 3, 2025 |
| Jan 2, 2025 | Joseph Monahan Chief Scientific Officer | AGrant or award Restricted Stock Unitsderivative | +52,667 | $0.00 | $0 | 52,667 | Jan 3, 2025 |
| Dec 31, 2024 | Kevin Balthaser Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -73,750 | $0.00 | $0 | 73,750 | Jan 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Kevin BalthaserChief Financial Officer
- Hugh M. DavisPresident and COO
- Maxine Gowendirector
- Jesse Wayne HallChief Medical Officer
- William D. Humphriesdirector
- James LoeropChief Business Officer
- Vincent Milanodirector
- Anand Mehradirector
- Christopher P. Molineauxdirector
- Joseph MonahanChief Scientific Officer
- Andrew N Schiffdirector
- Neal WalkerCEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.